FDA approves BMS’ blood cancer CAR T therapy after delay

BMS acquired Breyanzi following its $74bn takeover of Celgene in 2019 – the CAR-T therapy is one of the key assets critical to the potential payout of the merger in contingent ... As part of the merger agreement, BMS agreed to make a series of

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Amgen’s autoimmune franchise includes psoriasis blockbuster Otezla (apremilast), which it picked up from Celgene after it merged with Bristol Myers Squibb in 2019. ... The divestiture of Otezla was a key antitrust requirement imposed by the Federal

FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions

BMS picked up liso-cel 9 (lisocabtagene maraleucel) following its $74bn takeover of Celgene last year – the CAR-T therapy is one of the key assets critical to the potential payout ... BMS also agreed similar conditional payments, dependent on approval,

Switzerland: a life sciences hub

Celgene, now a subsidiary of Bristol-Myers Squibb (BMS), recently built its second production plant in Couvet, followed by the construction of a third production site in Boudry (Neuchâtel), to produce

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]